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The preparations characteristics
The presently available statin preparations are not a ho-
mogenous group chemically, which implicates a variability of 
indications and limitations of their use.
There are two generations of statins, among them there 
are six statins, which are commonly in use. The first genera-
tion, 3 natural statins, the funghi metabolism products, lo-
vastatin, simvastatin and pravastatin; the second generation, 
3 synthetic statins fluvastatin, atorvastatin and rosuvastatin. 
In 2001 cerivastatin for its serious adverse reactions, was with-
drawn from use.
Each statin has different pharmacokinetic properties, 
which causes differences in the force of hypolipemic and pleio-
tropic action and adverse reactions.
Hydrofilic statins, pravastatin and fluvastatin, are more 
liver selective, they penetrate the blood-brain barrier to a 
small extent and are characterized by a lesser drug penetra-
tion to other tissues. A limited penetration through cellular 
membranes may limit their beneficial pleiotropic effect (for ex-
ample in the vascular wall), but at the same time causes a rarer 
occurrence of adverse reactions (in muscles and in the central 
nervous system).
Lipophilic statins, simvastatin, lovastatin and atorvastatin, 
to a greater extent than hydrophilic statins penetrate through 
liver cell and endothelial membrane as well as the blood-brain 
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introduction
The first statin (mevastatin), as an agent selectively in-
hibiting the hydroxymethylglutaryl coenzyme A reductase, 
and thus blocking the cholesterol synthesis and decreasing its 
blood concentration, was discovered in 1976 in Japan. It has 
not, however, been introduced to treatment because of its tox-
icity demonstrated in animals.
In 1987 lovastatin was registered for lipid disorders treat-
ment in humans, in the United States. In the following years, 
mainly for their antiatherosclerotic effect, statins have gradu-
ally become drugs of growing popularity [1]. In 2004, statins 
were registered as over the counter drugs in Great Britain [2].
The significance of statins keeps rising because of their ap-
plication for lipid profile improvement, as well as for the activ-
ity reaching beyond their cholesterol-lowering effects (pleio-
tropic properties) [3].
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barrier, which may induce a more powerful pleiotropic effect. 
It also causes a different adverse reaction profile.
Action mechanism
Statins are the 3-hydroxy-3-methyl-3-glutaryl coenzyme 
A reductase inhibitors, an enzyme, which catalyzes also the 
hydroxy-methyl-glutaryl co-enzyme A transformation into 
mevalonian.
The effect of lipid profile improvement is associated main-
ly with the inhibition of mevalonian production, a substrate of 
endogenic cholesterol synthesis.
Studies performed during recent several years have stressed 
the beyond lipid, pleiotropic statins effect (anti-inflammatory, 
antioxidant and antithrombotic) [4]. Not all mechanisms and 
their clinical repercussions have been sufficiently demonstrat-
ed. It is known that the cholesterol synthesis, early stages in-
hibition (not influencing directly the cholesterol level itself), 
results in the intermediate metabolites synthesis blockage; 
isoprenoids (farnesyl phosphate and geranyl phosphate) which 
play a regulatory role in cells, and thus; influences the prolif-
eration and cell differentiation processes [5].
Indications for use of statins
So far the main indication for statins use is the increased 
total cholesterol and low-density lipoproteins (LDL) blood 
level.
According to more recent studies statins are used for more 
and more clinical indications [6]. In metabolic syndrome and 
type 2 diabetes, characterized by a lipid disorder called athero-
genic dislipidemia, statin therapy improves the lipid profile 
and decreases apolipoprotein B level (Heart Protection Study 
on simvastatin [7]).
Plausible trends in statin’s actions in 
rheumatic diseases
Regarding the statin mechanism of action, there are several 
potential options of this drug class that may concern rheumat-
ic diseases such as: 1) inhibition of atherosclerosis progression 
and lipid profile improvement, 2) osteoporosis prevention and 
the influence on bone metabolism, 3) inhibition inflammation 
(also through immunomodulation).
Antiatheroslerotic effect
Epidemiologic evidence demonstrates that in rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE) there is 
a premature, rapidly progressing atherosclerosis development, 
followed by cardiovascular complications [8,9]. In a large 
group of patients these complications are the reason for an in-
creased mortality and preterm disability. Classical cardiovas-
cular risk factors such as hypercholesterolemia, do not occur 
more often than cardiovascular complications in these groups 
[10]. The opinion dominates that atherosclerosis development 
is associated with chronic inflammation being the basis for the 
development of systemic connective tissue diseases.
Atherosclerosis is a chronic inflammatory reaction to ar-
terial endothelium damage, combined with oxidative stress, 
cholesterol deposition, enhanced blood coagulation and a fi-
broproliferative process [11]. The morphologic marker of ath-
erosclerosis represents structural and functional vascular en-
dothelium damage, mainly through inflammatory processes 
and lipoprotein metabolism disorders. There are numerous 
similarities in the pathomechanism of atherosclerosis and RA 
alteration development. In both diseases macrophage activa-
tion can be observed, the increase in tumor necrosis factor α 
- TNF-α level, interleukin 6 (IL-6), C-reactive protein – CRP 
and metalloproteinases, T cell activation and the Th1/Th2 ra-
tio altered in favor of Th1. All these parameters are higher in 
RA. A greater adhesion molecules expression can be seen in 
endothelial cells (intercellular and vascular adhesive molecule 
type 1, E- and P-selectins) and neoangiogenesis. Apart from 
that inflammatory cytokines stimulate cholesterol LDL frac-
tion oxidation.
It is the cardiovascular system that has been clinically 
evaluated as the statins activity point, so far. With increasing 
knowledge of the mechanism of atherogenesis , the cardiovas-
cular disease risk level can be determined by the assessment 
of the vascular wall and the inflammatory process activation; 
although the first studies of statins were targeted at the lipid 
profile assessment.
The mechanisms of the antiatherosclerotic statin effect in-
clude:
1) the vascular endothelium protective effect. The increase of 
endothelial expression of nitric monoxide production cata-
lyzing enzyme takes place through the Rho protein inhibi-
tion (guanosine triphosphate GTP small binding protein) 
and Akt, protein kinase [12]. This increases the vascular 
wall reactivity. Statin therapy decreases the type 1 an-
giotensine II receptor expression in the vascular smooth 
muscle cells, thus weakening the vasoconstrictive effect of 
angiotensin II [13]
2) anticoagulant effect. The beyond lipid effect of statins 
manifests itself in the inhibition of thrombogenesis stag-
es through influence on plasma coagulation factors and 
platelet activation. A decrease of thrombin production is 
a result of decreased tissue factor expression on vascular 
endothelial cells and in atheromatosus plaques, and of an 
increased thrombomodulin expression [14]. Statins (sim-
vastatin) disrupt platelet activation after vascular damage, 
through the protein degranulation inhibition [15]. A de-
crease in fibrinogen levels is observed
3) antioxidant effect. As a result of statin administration the 
lipoprotein LDL resistance to oxidation increases and the 
anti-oxidized LDL antibodies levels decrease [16]. The 
removal of free radicals and the influence on paraoxidase 
activity (high-density lipoprotein linked enzyme) is crucial 
for this mechanism of action
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ferent disease pathogenesis and the absence of inflammatory 
process in the degenerative lesions may be the reason [23].
Statins inhibit the induction of several proinflammatory 
cytokines; TNF-α, IL-1β, IL-6 and IL-8, and they decrease 
the CRP level, which is an exponent of the systemic inflamma-
tory process and an independent risk factor of cardiovascular 
diseases [24-26]. This occurs due to a decrease of IL-6 levels, 
the cytokine that stimulates CRP synthesis. The effect of CRP 
lowering is to be seen already after several weeks of treatment, 
and the extent of the decrease depends on its initial level. [26] 
Statins also inhibit the inducible nitric oxide synthase pro-
duced by macrophages; mainly through a decrease in protein 
prenylation processes.
Inhibition of monocyte inflammatory activity has been 
demonstrated in response to oxidized lipoproteins and it is 
mediated by transcriptive factors such as PPAR-γ and NFκB 
factor in vitro. [27]
Immunomodulatory effect of statins
Taking the autoimmune background of several rheumatic 
diseases into account, the immunomodulatory statins’ action 
on their pathogenetic mechanisms cannot be ignored.
Inhibition of isoprenylation is responsible for the statins’ 
immunomodulatory effect. Inducing the phenomenon of im-
munotolerance through the protein expression decrease in the 
major histocompatibility complex seems important in therapy 
[28].
Statins inhibit the interferon γ co-stimulation dependent 
expression of class II antigens of the major histocompatibility 
complex on the macrophages surface and inhibit the factors 
(co stimulating, that is CD40, CD8, CD86) on the antigen 
presenting cell surfaces. They decrease the cytokine produc-
tion through Th1 lymphocytes (IL-2, γ interferon, TNF-α); 
induce cytokine release from Th2 (IL-4, IL-5, IL-10) Th0 dif-
ferentiation to Th2. Apart from that statins block β2-integrin 
and CD11a/CD18 molecules, thus inhibiting the adhesion and 
co-stimulation of leukocytes. These mechanisms have been so 
far demonstrated in studies performed in vitro and were not 
convincingly confirmed in clinical trials.
Immunomodulatory effect seems to be particularly useful 
in the treatment of autoimmune diseases, which is however 
associated with a considerable risk. 
Reports on autoimmunization caused by statins provide 
the rationale speaking in favor of the strong immunomod-
ulative effect of statins. In the Noel et al. analysis [29,30], 
containing the reports from the years 1966–2005, 28 sta-
tin dependent disease occurrence of autoimmune origin was 
described including; 10 SLE cases, 3 cutaneous lupus cases, 
14 dermatomyositis cases and multiyosistis and pemphigoid 
case. In addition, in 2 SLE patients autoimmune hepatitis oc-
curred [31]. Moreover, in some of those individuals antinuclear 
antibodies, which persisted for several months after clinical 
symptoms resolution, were observed. Statins administration is 
therefore not free of adverse reactions.
4) the participation of osteoprotegerin (OPG) in the develop-
ment of atherosclerotic lesions still remains unclear. Ac-
cording to some researchers, for example Kiechl et al. [17], 
a high level of OPG is an independent risk factor for ath-
erosclerotic lesions progression and cardiovascular system 
complications. In view of these opinions the identification 
of statins influence on the OPG/RANKL/RANK system, 
also in the Celińska-Löwenhoff et al. study [18], seems 
worth emphasizing. The administration of 40 mg sim-
vastatin in patients with stable coronary artery disease re-
sulted in a significant increase in OPG level in one month 
of therapy, and maintained at the same level for the fol-
lowing 2 months. With a slight decrease in sRANKL the 
OPG:sRANKL ratio has also increased and the increase 
lasted for 3 months of follow-up.
Statins allow to obtain the clinically important aim in 
primary and secondary prevention of cardiovascular diseases; 
atheromatosus plaque stabilization, through the above mecha-
nisms. This effect is exerted through the weakening or sup-
pressing of the inflammatory process, antioxidant effect, vas-
cular endothelium protection and anticoagulant effect.
This has been demonstrated in studies with the use of an-
giographic methods for coronary artery atherosclerotic lesions 
assessment, for example the MAAS examination [19] and RE-
GRESS [20], and in cervical arteries, for example the KAPS 
study [21].
The TARA study led by McCarey’a et al. [22] has demon-
strated that by limiting the inflammatory process, atorvasta-
tin enables the decrease in cardiovascular complication risk in 
patients with RA, a highly active autoimmune inflammatory 
process.
The anti-inflammatory effect of statins in 
rheumatic diseases
An active and chronic inflammatory process is the nature 
of several rheumatic diseases. Systemic connective tissue dis-
eases provide a good example, among them 2 most common 
ones; RA and SLE. In rheumatoid arthritis the synovial mem-
brane of articulations affected by the inflammatory process is 
a rich source of proinflammatory factors, for example TNF-α, 
interleukin 1 (IL-1) or IL-6, which released to the circulation 
maintain the inflammatory process. In these diseases, the sup-
pression of the inflammatory process is the main aim of com-
prehensive treatment. In the Nogashimo et al. study [23] syn-
oviocyte cells obtained from RA and osteoarthropathy patients 
underwent the effect of two kinds of statins in vitro; lipofilic 
fluvastatin and hydrofilic pravastatin. Synoviocyte apoptosis 
induction, occurring through the mevalonian transformation 
blockage and first of all by protein geranylgeranylation inhibi-
tion and RhoA/RhoA kinase, was demonstrated after adminis-
tration of lipofilic statin. Such an effect was not demonstrated 
with the use of hydrophilic statin (pravastatin). A beneficial 
anti-iflammatory effect observed in RA patients, in this study, 
was not confirmed in spondyloarthropathic patients. A dif-
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Statins effect on bone metabolism
Through the inhibition of hydroxymethylglutaryl coen-
zyme A transformation into mevalonian, statins unspecifically 
inhibit the transformation of farnesyl phosphate. The mecha-
nism of this effect resembles the effect of bisfosfonians, which 
inhibit the transformation of mevalonian to farnesyl pyrophos-
phate. In the in vitro and in vivo studies, the statins’ influence 
on osseal metabolism, through the increase in bone formation, 
as well as through bone tissue resorption inhibition, has been 
demonstrated. This happens through increased bone morpho-
genetic protein type II (BMP-2) gene expression in bones, the 
BMP-2 mRNA promotor region activation. The decrease in 
the Rho p21 protein prenylation responsible for the binding 
of guanosine triphosphate increases the osteogenesis, which 
results in bone formation intensification. In osteoclasts on the 
contrary, the inhibition of the protein isoprenylation, neces-
sary for activation leads to its apoptosis. Another documented 
mechanism of bone mass increase is the role of nitric monox-
ide. Statins activate the Akt protein kinase, thus increasing 
nitric monoxide endothelial synthesis [32]. Such effects have 
previously been demonstrated in the in vitro studies and in 
animals, however now there is already strong evidence for a 
similar effect in humans. It is mainly the lipofilic statins that 
exert an effect on bone metabolism.
Data regarding clinical influence of statins on bone metab-
olism in terms of increased bone mineralization and fracture 
risk reduction are ambiguous. Two comparable retrospective 
studies of this issue demonstrated different results; one dem-
onstrated a significant reduction in fracture risk, the other did 
not demonstrate a beneficial effect of statins’ therapy [33,34]. 
Analyses of both studies were based on general practitioners 
practice in Great Britain and both studies analyzed groups of 
81,000 patients. The differences concerned taking account of 
factors perturbing the analysis; other drugs administration, 
cigarette smoking, lipid disorders, hormone replacement ther-
apy and body mass index (BMI). Including BMI may partially 
explain these differences to a certain extent (obesity potentially 
protects against fracture through body mass increase and bone 
shock absorption with falls).
During clinical studies on secondary prevention of cardio-
vascular events , with the use of pravastatin (LIPID) [35] and 
simvastatin (4S) [36], no decrease in bone fracture risk was 
reported. A limitation to the interpretation of usefulness of 
both studies was the participation of patients with low frac-
ture risk (mainly men) and the lack of differentiation between 
osteoporotic and traumatic bone fractures.
The benefit of statin use was clearly demonstrated by Chan 
et al. [37] in the study of 928 postmenopausal women, in 
whom a bone mineral density (spine and femur neck) increase 
of about 7–8 % was observed during the 4-year follow-up. 
A similar beneficial effect was confirmed by the retrospective 
study of Wanga et al. [38], in the United States, on a group of 
over 6,000 patients. 
This study demonstrated a nearly 50% fracture risk reduc-
tion in individuals taking statins. A slightly lower risk reduc-
tion (32%) was demonstrated by Rejnmark et al. [39]; its rate 
increased proportionally with the duration of statin therapy; 
the reduction did not concern individuals taking hypolipemic 
drugs from other groups.
Retrospective studies require an especially cautious atten-
tion. In the Women’s Health Initiative Observational Study 
[40], for example, with the participation of over 93,000 post-
menopausal women, statins were used in the older group, of-
ten with greater BMI, more often with previous myocardial 
infarction, and in women taking diuretics, and less often in 
individuals on hormone replacement therapy. A decrease in 
fracture risk was not confirmed in individuals on statins.
The diversity of study results assessing the alteration of 
bone fracture risk includes the BMI assessment as an evident 
factor of fracture risk. In Rejnmark’s randomized study with 
the use of simvastatin in women with postmenopausal osteope-
nia, the BMI alterations and the bone turnover markers were 
assessed. [39]. In the 1- year follow-up a slight increase in BMI 
as well as a slight differentiation of bone turnover markers in 
the studied and  control groups, were demonstrated.
Recently, two large meta-analyses were performed, one by 
Bajer et al. in 2004 [41] and other by Hatzigeorgiou et al. in 
2005 [42]. Both of them included prospective observational 
and clinical randomized studies. In conclusion, statistically 
significant fracture risk decrease and bone mass density in-
crease in the femur neck (only in retrospective studies) and the 
lack of such a relation for the lumbar spine were reported.
Experimental studies demonstrate a beneficial effect of sta-
tins on bone metabolism (including the anabolic effect), which 
has not however been confirmed in clinical studies. The reason 
for these differences is believed to be the low absorbency of 
statins in the intestines and the first pass through the liver ef-
fect, which in total leads to low statin bone tissue availability. 
It cannot however be excluded that in a broader perspective 
statins may contribute to the decrease in fracture risk. 
SuMMarY
At present there is no reliable data allowing the intiation 
of statin administration as part of standard complementary 
therapy in rheumatic diseases. The pharmacotherapy indica-
tions in rheumatic diseases (after lipid profile assessment) are 
the same as those in the general population, therefore statin 
administration in chronic inflammatory diseases and hyper-
lipidemia is, in our opinion, justified.
Results of studies with use of specific agents suggest their 
usefulness in certain diseases. It is known that pravastatin is 
not appropriate for patients with osteoporosis and those with 
rheumathoid arthritis, atorvastatin seems to be the optimal 
choice, as already successfully administered in several studies 
[43].
The common use of statins and their indications that are 
clearly stated and not raising doubts (as cardiovascular dis-
eases) will provide validation of their usefulness and the as-
sessment of their safety in a large group of rheumatic disease 
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patients. This is suggested by the attempts to make analysis 
from the point of view of bone metabolism in clinical studies, 
which originally have been planned with a completely differ-
ent aim.
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